Guidant gambles on CHF (Congestive Heart Failure) with $425 million Johnson & Johnson cardiac deal
This article was originally published in Clinica
Executive Summary
Guidant and Johnson & Johnson have dramatically upped the stakes in the cardiac market through a complex series of deals. Guidant is to buy potentially breakthrough cardiac technology at the same time as freeing itself from litigation with J&J. In return, J&J will get up to $425 million from Guidant and access to rapid-exchange delivery technology.